Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Seminars in Immunopathology
Published in: Seminars in Immunopathology 5/2021

01-10-2021 | Review

IgA glycosylation and immune complex formation in IgAN

Authors: Hitoshi Suzuki, Jan Novak

Published in: Seminars in Immunopathology | Issue 5/2021

Login to get access

Abstract

IgA nephropathy (IgAN) is the most common primary glomerulonephritis worldwide. This disease, discovered in 1968, is characterized by IgA-IgG glomerular immunodeposits with a mesangial pattern. It is thought that these immunodeposits originate from the immune complexes formed in the circulation. It is hypothesized that the pathogenesis of IgAN is driven by aberrant glycoforms of IgA1 (galactose-deficient IgA1, Gd-IgA1). Gd-IgA1, in genetically susceptible individuals, represents the initiating factor for the formation of circulating immune complexes due to its recognition by IgG autoantibodies and the subsequent formation of pathogenic IgA1-IgG immune complexes. Complement activation through alternative and/or lectin pathways is likely playing an important role in the pathogenic properties of these complexes and may further upregulate local inflammatory responses and glomerular injury.
Literature
1.
Chauveau D, Droz D (1993) Follow-up evaluation of the first patients with IgA nephropathy described at Necker Hospital. Contrib Nephrol 104:1–5PubMedCrossRef
2.
D’Amico G (2004) Natural history of idiopathic IgA nephropathy and factors predictive of disease outcome. Semin Nephrol 24:179–196PubMedCrossRef
3.
Imai H, Miura N (2012) A treatment dilemma in adult immunoglobulin A nephropathy: what is the appropriate target, preservation of kidney function or induction of clinical remission? Clin Exp Nephrol 16:195–201PubMedCrossRef
4.
Chen A, Yang SS, Lin TJ, Ka SM (2018) IgA nephropathy: clearance kinetics of IgA-containing immune complexes. Semin Immunopathology 40:539–543CrossRef
5.
6.
Magistroni R, D’Agati VD, Appel GB, Kiryluk K (2015) New developments in the genetics, pathogenesis, and therapy of IgA nephropathy. Kidney Int 88:974–989PubMedPubMedCentralCrossRef
7.
Sanfilippo F, Croker BP, Bollinger RR (1982) Fate of four cadaveric donor renal allografts with mesangial IgA deposits. Transplantation 33:370–376PubMedCrossRef
8.
van der Boog PJ, de Fijter JW, Bruijn JA, van Es LA (1999) Recurrence of IgA nephropathy after renal transplantation. Ann Med Interne 150:137–142
9.
Hiki Y, Odani H, Takahashi M, Yasuda Y, Nishimoto A, Iwase H, Shinzato T, Kobayashi Y, Maeda K (2001) Mass spectrometry proves under-O-glycosylation of glomerular IgA1 in IgA nephropathy. Kidney Int 259:1077–1085CrossRef
10.
Allen AC, Bailey EM, Brenchley PE, Buck KS, Barratt J, Feehally J (2001) Mesangial IgA1 in IgA nephropathy exhibits aberrant O-glycosylation: observations in three patients. Kidney Int 60:969–973PubMedCrossRef
11.
Coppo R, Basolo B, Martina G, Rollino C, De Marchi M, Giacchino F, Mazzucco G, Messina M, Piccoli G (1982) Circulating immune complexes containing IgA, IgG and IgM in patients with primary IgA nephropathy and with Henoch-Schoenlein nephritis. Correlation with clinical and histologic signs of activity. Clin Nephrol 18:230–239PubMed
12.
Coppo R, Basolo B, Piccoli G, Mazzucco G, Bulzomi MR, Roccatello D, De Marchi M, CarbonaraAO B, di Belgiojoso G (1984) IgA1 and IgA2 immune complexes in primary IgA nephropathy and Henoch-Schonlein nephritis. Clin Exp Iimmunol 57:583–590
13.
Czerkinsky C, Koopman WJ, Jackson S, Collins JE, Crago SS, Schrohenloher RE, Julian BA, Galla JH, Mestecky J (1986) Circulating immune complexes and immunoglobulin A rheumatoid factor in patients with mesangial immunoglobulin A nephropathies. J Clin Invest 77:1931–1938PubMedPubMedCentralCrossRef
14.
Novak J, Vu HL, Novak L, Julian BA, Mestecky J, Tomana M (2002) Interactions of human mesangial cells with IgA and IgA-containing immune complexes. Kidney Int 62:465–475PubMedCrossRef
15.
Novak J, Tomana M, Matousovic K, Brown R, Hall S, Novak L, Julian BA, Wyatt RJ, Mestecky J (2005) IgA1-containing immune complexes in IgA nephropathy differentially affect proliferation of mesangial cells. Kidney Int 67:504–513PubMedCrossRef
16.
Tamouza H, Chemouny JM, Raskova Kafkova L, Berthelot L, Flamant M, Demion M, Mesnard L, Paubelle E, Walker F, Julian BA, Tissandie E, Tiwari MK, Camara NO, Vrtovsnik F, BenhamouM NJ, Monteiro RC, Moura IC (2012) The IgA1 immune complex-mediated activation of the MAPK/ERK kinase pathway in mesangial cells is associated with glomerular damage in IgA nephropathy. Kidney Int 82:1284–1296PubMedPubMedCentralCrossRef
17.
Suzuki Y, Matsuzaki K, Suzuki H, Okazaki K, Yanagawa H, Ieiri N, Sato M, Sato T, Taguma Y, Matsuoka J, Horikoshi S, Novak J, Hotta O, Tomino Y (2014) Serum levels of galactose-deficient immunoglobulin (Ig) A1 and related immune complex are associated with disease activity of IgA nephropathy. Clin Exp Nephrol 18:770–777PubMedPubMedCentralCrossRef
18.
Bene MC, Faure G, Hurault de Ligny B, Kessler M, Duheille J (1983) Immunoglobulin A nephropathy. Quantitative immunohistomorphometry of the tonsillar plasma cells evidences an inversion of the immunoglobulin A versus immunoglobulin G secreting cell balance. J Clin Invest 71:1342–1347PubMedPubMedCentralCrossRef
19.
20.
Bellur SS, Troyanov S, Cook HT, Roberts ID, Working Group of International IgA Nephropathy Network and Renal Pathology Society (2011) Immunostaining findings in IgA nephropathy: correlation with histology and clinical outcome in the Oxford classification patient cohort. Nephrol Dial Transplant 26:2533–2536PubMedCrossRef
21.
Suzuki K, Honda K, Tanabe K, Toma H, Nihei H, Yamaguchi Y (2003) Incidence of latent mesangial IgA deposition in renal allograft donors in Japan. Kidney Int 63:2286–2294PubMedCrossRef
22.
Nakazawa S, Imamura R, Kawamura M, Kato T, Abe T, Namba T, Iwatani H, Yamanaka K, Uemura M, Kishikawa H, Nishimura K, Oka K, Tajiri M, Wada Y, Nonomura N (2019) Difference in IgA1 O-glycosylation between IgA deposition donors and IgA nephropathy recipients. Biochem Biophys Res Commun 508:1106–1112PubMedCrossRef
23.
Gaber LW, Khan FN, Graviss EA, Nguyen DT, Moore LW, Truong LD, Barrios RJ, Suki WN (2020) Prevalence, characteristics, and outcomes of incidental IgA glomerular deposits in donor kidneys. Kidney Int Rep 5:1914–1924PubMedPubMedCentralCrossRef
24.
Conley ME, Cooper MD, Michael AF (1980) Selective deposition of immunoglobulin A1 in immunoglobulin A nephropathy, anaphylactoid purpura nephritis, and systemic lupus erythematosus. J Clin Invest 66:1432–1436PubMedPubMedCentralCrossRef
25.
Tomino Y, Endoh M, Nomoto Y, Sakai H (1981) Immunoglobulin A1 and IgA nephropathy. N Engl J Med 305:1159–1160PubMedCrossRef
26.
27.
Papista C, Berthelot L, Monteiro RC (2011) Dysfunctions of the Iga system: a common link between intestinal and renal diseases. Cell Mol Immunol 8:126–134PubMedPubMedCentralCrossRef
28.
29.
30.
Novak J, Julian BA, Tomana M, Mestecky J (2008) IgA glycosylation and IgA immune complexes in the pathogenesis of IgA nephropathy. Semin Nephrol 28:78–87PubMedPubMedCentralCrossRef
31.
Renfrow MB, Cooper HJ, Tomana M, Kulhavy R, Hiki Y, Toma K, Emmett MR, Mestecky J, Marshall AG (2005) Novak J (2005) Determination of aberrant O-glycosylation in the IgA1 hinge region by electron capture dissociation Fourier transform-ion cyclotron resonance mass spectrometry. J Biol Chem 280:19136–19145PubMedCrossRef
32.
Moldoveanu Z, Wyatt RJ, Lee JY, Tomana M, Julian BA, Mestecky J, Huang WQ, Anreddy SR, Hall S, Hastings MC, Lau KK, Cook WJ, Novak J (2007) Patients with IgA nephropathy have increased serum galactose-deficient IgA1 levels. Kidney Int 71:1148–1154PubMedCrossRef
33.
Suzuki H, Moldoveanu Z, Hall S, Brown R, Vu HL, Novak L, Julian BA, Tomana M, Wyatt RJ, Edberg JC, Alarcón GS, Kimberly RP, Tomino Y, Mestecky J, Novak J (2008) IgA1-secreting cell lines from patients with IgA nephropathy produce aberrantly glycosylated IgA1. J Clin Invest 118:629–639PubMedPubMedCentral
34.
Kiryluk K, Li Y, Moldoveanu Z, Suzuki H, Reily C, Hou P, Xie J, Mladkova N, Prakash S, Fischman C, Shapiro S, LeDesma RA, Bradbury D, Ionita-Laza I, Eitner F, Rauen T, Maillard N, Berthoux F, Floege J, Chen N, Zhang H, Scolari F, Wyatt RJ, Julian BA, Gharavi AG, Novak J (2017) GWAS for serum galactose-deficient IgA1 implicates critical genes of the O-glycosylation pathway. PLoS Genet 10:e1006609
35.
Barratt J, Eitner F (2009) Glomerular disease: sugars and immune complex formation in IgA nephropathy. Nat Rev Nephrol 5:612–614PubMedCrossRef
36.
Tomana M, Novak J, Julian BA, Matousovic K, Konecny K, Mestecky J (1999) Circulating immune complexes in IgA nephropathy consist of IgA1 with galactose-deficient hinge region and antiglycan antibodies. J Clin Invest 104:73–81PubMedPubMedCentralCrossRef
37.
Suzuki H, Allegri L, Suzuki Y, Hall S, Moldoveanu Z, Wyatt RJ, Novak J, Julian BA (2016) Galactose-deficient IgA1 as a candidate urinary polypeptide marker of IgA nephropathy? Dis Markers 2016:7806438PubMedPubMedCentralCrossRef
38.
Yasutake J, Suzuki Y, Suzuki H, Hiura N, Yanagawa H, Makita Y, Kaneko E, Tomino Y (2015) Novel lectin-independent approach to detect galactose-deficient IgA1 in IgA nephropathy. Nephrol Dial Transplant 30:1315–1321PubMedPubMedCentralCrossRef
39.
Gharavi AG, Moldoveanu Z, Wyatt RJ, Barker CV, Woodford SY, Lifton RP, Mestecky J, Novak J, Julian BA (2008) Aberrant IgA1 glycosylation is inherited in familial and sporadic IgA nephropathy. J Am Soc Nephrol 19:1008–1014PubMedPubMedCentralCrossRef
40.
Matousovic K, Novak J, Yanagihara T, Tomana M, Moldoveanu Z, Kulhavy R, Julian BA, Konecny K, Mestecky J (2006) IgA-containing immune complexes in the urine of IgA nephropathy patients. Nephrol Dial Transplant 21:2478–2484PubMedCrossRef
41.
Novak J, Julian BA, Mestecky J, Renfrow MB (2012) Glycosylation of IgA1 and pathogenesis of IgA nephropathy. Semin Immunopathol 34:365–382PubMedCrossRef
42.
Mestecky J, Raska M, Julian BA, Gharavi AG, Renfrow MB, Moldoveanu Z, Novak L, Matousovic K, Novak J (2013) IgA nephropathy: molecular mechanisms of the disease. Annu Rev Pathol 8:217–240PubMedCrossRef
43.
Suzuki H, Fan R, Zhang Z, Brown R, Hall S, Julian BA, Chatham WW, Suzuki Y, Wyatt RJ, Moldoveanu Z, Lee JY, Robinson J, Tomana M, Tomino Y, Mestecky J, Novak J (2009) Aberrantly glycosylated IgA1 in IgA nephropathy patients is recognized by IgG antibodies with restricted heterogeneity. J Clin Invest 119:1668–1677PubMedPubMedCentral
44.
Suzuki H, Kiryluk K, Novak J, Moldoveanu Z, Herr AB, Renfrow MB, Wyatt RJ, Scolari F, Mestecky J, Gharavi AG, Julian BA (2011) The pathophysiology of IgA nephropathy. J Am Soc Nephrol 22:1795–1803PubMedPubMedCentralCrossRef
45.
Zhao N, Hou P, Lv J, Moldoveanu Z, Li Y, Kiryluk K, Gharavi AG, Novak J, Zhang H (2012) The level of galactose-deficient IgA1 in the sera of patients with IgA nephropathy is associated with disease progression. Kidney Int 82:790–796PubMedPubMedCentralCrossRef
46.
Camilla R, Suzuki H, Daprà V, Loiacono E, Peruzzi L, Amore A, Ghiggeri GM, Mazzucco G, Scolari F, Gharavi AG, Appel GB, Troyanov S, Novak J, Julian BA, Coppo R (2011) Oxidative stress and galactose-deficient IgA1 as markers of progression in IgA nephropathy. Clin J Am Soc Nephrol 6:1903–1911PubMedPubMedCentralCrossRef
47.
Berthoux F, Suzuki H, Thibaudin L, Yanagawa H, Maillard N, Mariat C, Tomino Y, Julian BA, Novak J (2012) Autoantibodies targeting galactose-deficient IgA1 associate with progression of IgA nephropathy. J Am Soc Nephrol 23:1579–1587PubMedPubMedCentralCrossRef
48.
Maixnerova D, Ling C, Hall S, Reily C, Brown R, Neprasova M, Suchanek M, Honsova E, Zima T, Novak J, Tesar V (2019) Correction: Galactose-deficient IgA1 and the corresponding IgG autoantibodies predict IgA nephropathy progression. PLoS ONE 12:e0219947CrossRef
49.
Yanagawa H, Suzuki H, Suzuki Y, Kiryluk K, Gharavi AG, Matsuoka K, Makita Y, Julian BA, Novak J, Tomino Y (2014) A panel of serum biomarkers differentiates IgA nephropathy from other renal diseases. PLoS ONE 9:e98081PubMedPubMedCentralCrossRef
50.
Aucouturier P, Monteiro RC, Noël LH, Preud’homme JL, Lesavre P (1989) Glomerular and serum immunoglobulin G subclasses in IgA nephropathy. Clin Immunol Immunopathol 51:338–347PubMedCrossRef
51.
Rizk DV, Saha MK, Hall S, Novak L, Brown R, Huang ZQ, Fatima H, Julian BA, Novak J (2019) Glomerular immunodeposits of patients with IgA nephropathy are enriched for IgG autoantibodies specific for galactose-deficient IgA1. J Am Soc Nephrol 30:2017–2026PubMedPubMedCentralCrossRef
52.
Moldoveanu Z, Suzuki H, Reily C, Satake K, Novak L, Xu N, Huang ZQ, Knoppova B, Khan A, Hall S, Yanagawa H, Brown R, Winstead CJ, O'Quinn DB, Weinmann A, Gharavi AG, Kiryluk K, Julian BA, Weaver CT, Suzuki Y, Novak J (2021) Experimental evidence of pathogenic role of IgG autoantibodies in IgA nephropathy. J Autoimmun. 118:102593. https://​doi.​org/​10.​1016/​j.​jaut.​2021.​102593. Jan 25. PMID: 33508637; PMCID: PMC7997636.
53.
Yamaji K, Suzuki Y, Suzuki H, Satake K, Horikoshi S, Novak J, Tomino Y (2014) The kinetics of glomerular deposition of nephritogenic IgA. PLoS ONE 9:e113005PubMedPubMedCentralCrossRef
54.
Sofue T, Inui M, Hara T, Moritoki M, Nishioka S, Nishijima Y, Moriwaki K, Hayashida Y, Ueda N, Kushida Y, Haba R, Nishiyama A, Kakehi Y, Kohno M (2013) Latent IgA deposition from donor kidneys does not affect transplant prognosis, irrespective of mesangial expansion. Clin Transplant 27(Suppl 26):14–21PubMedCrossRef
55.
56.
Feehally J, Beattie TJ, Brenchley PE, Coupes BM, Mallick NP, Postlethwaite RJ (1986) Sequential study of the IgA system in relapsing IgA nephropathy. Kidney Int 30:924–931PubMedCrossRef
57.
Macpherson AJ, Yilmaz B, Limenitakis JP, Ganal-Vonarburg SC (2018) IgA function in relation to the intestinal microbiota. Annu Rev Immunol 36:359–381PubMedCrossRef
58.
59.
60.
Hapfelmeier S, Lawson MA, Slack E, Kirundi JK, Stoel M, Heikenwalder M, Cahenzli J, Velykoredko Y, Balmer ML, Endt K, Geuking MB, Curtiss R 3rd, McCoy KD, Macpherson AJ (2010) Reversible microbial colonization of germ-free mice reveals the dynamics of IgA immune responses. Science 328:1705–1709PubMedPubMedCentralCrossRef
61.
Allen AC, Feehally J (2000) IgA1 glycosylation and the pathogenesis of IgA nephropathy. Am J Kidney Dis 35:551–556PubMedCrossRef
62.
Suzuki H, Suzuki Y, Narita I, Aizawa M, Kihara M, Yamanaka T, Kanou T, Tsukaguchi H, Novak J, Horikoshi S, Tomino Y (2008) Toll-like receptor 9 affects severity of IgA nephropathy. J Am Soc Nephrol 19:2384–2395PubMedPubMedCentralCrossRef
63.
Novak J, Moldoveanu Z, Julian BA, Raska M, Wyatt RJ, Suzuki Y, Tomino Y, Gharavi AG, Mestecky J, Suzuki H (2011) Aberrant glycosylation of IgA1 and anti-glycan antibodies in IgA nephropathy: role of mucosal immune system. Adv Otorhinolaryngol 72:60–63PubMed
64.
Litinskiy MB, Nardelli B, Hilbert DM, He B, Schaffer A, Casali P, Cerutti A (2002) DCs induce CD40-independent immunoglobulin class switching through BLyS and APRIL. Nat Immunol 3:822–829PubMedPubMedCentralCrossRef
65.
Makita Y, Suzuki H, Kano T, Takahata A, Julian BA, Novak J, Suzuki Y (2020) TLR9 activation induces aberrant IgA glycosylation via APRIL- and IL-6-mediated pathways in IgA nephropathy. Kidney Int 97:340–349PubMedCrossRef
66.
Harper SJ, Allen AC, Pringle JH, Feehally J (1996) Increased dimeric IgA producing B cells in the bone marrow in IgA nephropathy determined by in situ hybridisation for J chain mRNA. J Clin Pathol 49:38–42PubMedPubMedCentralCrossRef
67.
Bene MC, Faure G, Duheille J (1982) IgA nephropathy: characterization of the polymeric nature of mesangial deposits by in vitro binding of free secretory component. Clin Exp Immunol 47:527–534PubMedPubMedCentral
68.
69.
Suzuki Y, Suzuki H, Nakata J, Sato D, Kajiyama T, Watanabe T, Tomino Y (2011) Pathological role of tonsillar B cells in IgA nephropathy. Clin Dev Immunol 2011:639074PubMedPubMedCentralCrossRef
70.
Floege J, Feehally J (2016) The mucosa-kidney axis in IgA nephropathy. Nat Rev Nephrol 12:147–156PubMedCrossRef
71.
Horie A, Hiki Y, Odani H, Yasuda Y, Takahashi M, Kato M, Iwase H, Kobayashi Y, Nakashima I, Maeda K (2003) IgA1 molecules produced by tonsillar lymphocytes are under-O-glycosylated in IgA nephropathy. Am J Kidney Dis 42:486–496PubMedCrossRef
72.
Nakata J, Suzuki Y, Suzuki H, Sato D, Kano T, Yanagawa H, Matsuzaki K, Horikoshi S, Novak J, Tomino Y (2014) Changes in nephritogenic serum galactose-deficient IgA1 in IgA nephropathy following tonsillectomy and steroid therapy. PLoS ONE 9:e89707PubMedPubMedCentralCrossRef
73.
Inoue T, Sugiyama H, Hiki Y, Takiue K, Morinaga H, Kitagawa M, Maeshima Y, Fukushima K, Nishizaki K, Akagi H, Narimatsu Y, Narimatsu H, Makino H (2010) Differential expression of glycogenes in tonsillar B lymphocytes in association with proteinuria and renal dysfunction in IgA nephropathy. Clin Immunol 136:447–455PubMedCrossRef
74.
Bene MC, Hurault De Ligny B, Kessler M, Faure GC (1991) Confirmation of tonsillar anomalies in IgA nephropathy: a multicenter study. Nephron 58:425–428PubMedCrossRef
75.
76.
Komatsu H, Fujimoto S, Hara S, Sato Y, Yamada K, Kitamura K (2008) Effect of tonsillectomy plus steroid pulse therapy on clinical remission of IgA nephropathy: a controlled study. Clin J Am Soc Nephrol 3:1301–1307PubMedPubMedCentralCrossRef
77.
Xie Y, Nishi S, Ueno M, Imai N, Sakatsume M, Narita I, Suzuki Y, Akazawa K, Shimada H, Arakawa M, Gejyo F (2003) The efficacy of tonsillectomy on long-term renal survival in patients with IgA nephropathy. Kidney Int 63:1861–1867PubMedCrossRef
78.
Hirano K, Matsuzaki K, Yasuda T, Nishikawa M, Yasuda Y, Koike K, Maruyama S, Yokoo T, Matsuo S, Kawamura T, Suzuki Y (2019) Association between tonsillectomy and outcomes in patients with immunoglobulin A nephropathy. JAMA Netw Open 2:e194772PubMedPubMedCentralCrossRef
79.
Maruyama S, Gohda T, Suzuki Y, Suzuki H, Sonoda Y, Ichikawa S, Li Z, Murakoshi M, Horikoshi S, Tomino Y (2016) Beneficial effects of tonsillectomy plus steroid pulse therapy on inflammatory and tubular markers in patients with IgA nephropathy. Kidney Res Clin Pract 35:233–236PubMedPubMedCentralCrossRef
80.
81.
Wang M, Lv J, Zhang X, Chen P, Zhao M, Zhang H (2020) Secondary IgA nephropathy shares the same immune features with primary IgA nephropathy. Kidney Int Rep 5:165–172PubMedCrossRef
82.
Fellstrom BC, Barratt J, Cook H, Coppo R, Feehally J, de Fijter JW, Floege J, Hetzel G, Jardine AG, Locatelli F, Maes BD, Mercer A, Ortiz F, Praga M, Sørensen SS, Tesar V, Del Vecchio L, NEFIGAN Trial Investigators (2017) Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial. Lancet 389:2117–2127PubMedCrossRef
83.
Kano T, Suzuki H, Makita Y, Fukao Y, Suzuki Y (2021) Nasal-associated lymphoid tissue is the major induction site for nephritogenic IgA in murine IgA nephropathy. Kidney Int in press
84.
Miyazaki T, Hirokami Y, Matsuhashi N, Takatsuka H, Naito M (1999) Increased susceptibility of thymocytes to apoptosis in mice lacking AIM, a novel murine macrophage-derived soluble factor belonging to the scavenger receptor cysteine-rich domain superfamily. J Exp Med 189:413–422PubMedPubMedCentralCrossRef
85.
Irabu H, Shimizu M, Kaneko S, Inoue N, Mizuta M, Tasaki Y, Ohta K, Yachie A, Wada T (2021) Apoptosis inhibitor of macrophage as a biomarker for disease activity in Japanese children with IgA nephropathy and Henoch-Schonlein purpura nephritis. Pediatr Res 89:667–672PubMedCrossRef
86.
Takahata A, Arai S, Hiramoto E, Kitada K, Kato R, Makita Y, Suzuki H, Nakata J, Araki K, Miyazaki T, Suzuki Y (2020) Crucial role of AIM/CD5L in the development of glomerular inflammation in IgA nephropathy. J Am Soc Nephrol 31:2013–2024PubMedPubMedCentralCrossRef
87.
Hastings MC, Moldoveanu Z, Julian BA, Novak J, Sanders JT, McGlothan KR, Gharavi AG, Wyatt RJ (2010) Galactose-deficient IgA1 in African Americans with IgA nephropathy: serum levels and heritability. Clin J Am Soc Nephrol 5:2069–2074PubMedPubMedCentralCrossRef
88.
Huang ZQ, Raska M, Stewart TJ, Reily C, King RG, Crossman DK, Crowley MR, Hargett A, Zhang Z, Suzuki H, Hall S, Wyatt RJ, Julian BA, Renfrow MB, Gharavi AG, Novak J (2016) Somatic mutations modulate autoantibodies against galactose-deficient IgA1 in IgA nephropathy. J Am Soc Nephrol 27:3278–3284PubMedPubMedCentralCrossRef
89.
Lai KN, Tang SC, Schena FP, Novak J, Tomino Y, Fogo AB, Glassock RJ (2016) IgA nephropathy Nat Rev Dis Primers 2:16001PubMedCrossRef
90.
Maillard N, Wyatt RJ, Julian BA, Kiryluk K, Gharavi A, Fremeaux-Bacchi V, Novak J (2015) Current understanding of the role of complement in IgA nephropathy. J Am Soc Nephrol 26:1503–1512PubMedPubMedCentralCrossRef
91.
van den Wall Bake AW, Daha MR, van Es LA (1989) Immunopathogenetic aspects of IgA nephropathy. Nephrologie 10:141–145PubMed
92.
Kennel-De March A, Bene MC, Hurault de Ligny B, Kessler M, Faure GC (1997) Enhanced expression of CD31 and CD54 on tonsillar high endothelial venules in IgA nephropathy. Clin Immunol Immunopathol 84:158–165PubMedCrossRef
93.
Buren M, Yamashita M, Suzuki Y, Tomino Y, Emancipator SN (2007) Altered expression of lymphocyte homing chemokines in the pathogenesis of IgA nephropathy. Contrib Nephrol 157:50–55PubMed
94.
Novak J, Moldoveanu Z, Renfrow MB et al (2007) IgA nephropathy and Henoch-Schoenlein purpura nephritis: aberrant glycosylation of IgA1, formation of IgA1-containing immune complexes, and activation of mesangial cells. Contrib Nephrol 157:134–138PubMedCrossRef
95.
Metadata
Title
IgA glycosylation and immune complex formation in IgAN
Authors
Hitoshi Suzuki
Jan Novak
Publication date
01-10-2021
Publisher
Springer Berlin Heidelberg
Published in
Seminars in Immunopathology / Issue 5/2021
Print ISSN: 1863-2297
Electronic ISSN: 1863-2300
DOI
https://doi.org/10.1007/s00281-021-00883-8

Other articles of this Issue 5/2021

Seminars in Immunopathology 5/2021 Go to the issue

Review

Are there animal models of IgA nephropathy?

Correction

Correction to: How will artificial intelligence and bioinformatics change our understanding of IgA Nephropathy in the next decade?

Review

How will artificial intelligence and bioinformatics change our understanding of IgA Nephropathy in the next decade?

Introduction

IgA nephropathy: a perspective for 2021

Review

The mucosal immune system and IgA nephropathy

Review

Is IgA nephropathy the same disease in different parts of the world?
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits